Cloning, characterization, and heterologous expression of a candidate Hirudin gene from the salivary gland transcriptome of Hirudo nipponia
Shi P, Wei J, You H, Chen S, Tan F, Lu Z (2023) · Scientific Reports · n=0
Study Profile
- Design
- molecular cloning, characterization, and Pichia pastoris heterologous expression of a candidate hirudin gene (c16237_g1) from Hirudo nipponia salivary-gland transcriptome; recombinant protein characterization and in-vitro antithrombin assays (Chongqing Academy of Chinese Materia Medica)
- Sample size (n)
- 0
- Intervention
- Recombinant H. nipponia hirudin produced via Pichia pastoris GS115 expression system; antithrombin activity assayed in-vitro
- Comparator
- H. medicinalis hirudin and H. manillensis hirudin (literature comparison)
- Primary endpoint
- Recombinant hirudin yield, purity, and antithrombin activity
- Primary result
- Recombinant H. nipponia hirudin expressed at 6.68 mg/L culture; purified hirudin concentration 1.67 mg/mL with antithrombin activity of 14,000 ATU/mL; established first heterologous expression and biotechnological production of H. nipponia hirudin, addressing Chinese market demand for engineered hirudin-based drugs
- Follow-up duration
- Not applicable
- PMID
- 36973525
Key Findings
- First Pichia pastoris recombinant production of H. nipponia hirudin
- Yield 6.68 mg/L; antithrombin activity 14,000 ATU/mL
- Establishes Chinese biotech pathway for H. nipponia hirudin drug candidates
- Conserved PKP and DFxxIP motifs identified — core thrombin-binding pocket preserved
- Provides species-specific expression workflow distinct from existing H. medicinalis or H. manillensis programs
Limitations
- Recombinant biochemistry only — no in-vivo pharmacology or clinical data
- Yield (6.68 mg/L) below industrial-scale recombinant hirudin manufacturing
- No comparison to natural hirudin biological activity in human plasma
- Pharmacokinetic, immunogenicity, and chronic-toxicology data absent
- H. nipponia is not the K040187 device leech
Clinical Implications
Shi 2023 establishes biotechnological infrastructure for engineered H. nipponia hirudin drug development in China. For ASH, the study reinforces that the global hirudin drug-development pipeline now spans multiple leech species and recombinant systems — distinct from the K040187 whole-leech device pathway used in US clinical practice. No direct US clinical implications; relevance is biotechnology and global regulatory landscape.
Related Trials
Medicinal leech therapy in venous congestion of microsurgical flaps: a randomized comparison with heparin pinprick scarification
Merlino G, Carbone S, Servillo G, Marletta DA (2020)
Adjunctive medicinal leech therapy for venous congestion in free flaps: a German multicenter randomized trial
Lehnhardt M, Daigeler A, Behr B, Schmidt SV, Wallner C (2021)
Medicinal leeches and the microsurgeon: a four-year study, clinical series and risk benefit review
Whitaker IS, Josty IC, Hawkins S, Azzopardi E, Naderi N, Graf J, Damaris L, Lineaweaver WC, Kon M (2011)
Medicinal leeches for surgically uncorrectable venous congestion after free flap breast reconstruction
Pannucci CJ, Nelson JA, Chung CU, Fischer JP, Kanchwala SK, Kovach SJ, Serletti JM, Wu LC (2014)